[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ars Pharmaceuticals Inc (SPRY)

Ars Pharmaceuticals Inc (SPRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 561,062
  • Shares Outstanding, K 99,303
  • Annual Sales, $ 84,280 K
  • Annual Income, $ -171,300 K
  • EBIT $ -202 M
  • EBITDA $ -207 M
  • 60-Month Beta 0.98
  • Price/Sales 7.19
  • Price/Cash Flow N/A
  • Price/Book 9.88

Options Overview Details

View History
  • Implied Volatility 87.48% (-4.08%)
  • Historical Volatility 62.95%
  • IV Percentile 19%
  • IV Rank 10.77%
  • IV High 341.30% on 03/30/26
  • IV Low 56.85% on 08/25/25
  • Expected Move (DTE 5) 0.81 (14.29%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 190
  • Volume Avg (30-Day) 358
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 11,064
  • Open Int (30-Day) 8,600
  • Expected Range 4.84 to 6.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.34
  • Number of Estimates 2
  • High Estimate $-0.30
  • Low Estimate $-0.37
  • Prior Year $-0.52
  • Growth Rate Est. (year over year) +34.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.91 +15.07%
on 08/03/26
7.69 -26.53%
on 07/15/26
-1.96 (-25.76%)
since 07/14/26
3-Month
4.91 +15.07%
on 08/03/26
10.87 -48.02%
on 06/24/26
-2.29 (-28.84%)
since 05/14/26
52-Week
4.91 +15.07%
on 08/03/26
15.09 -62.56%
on 08/21/25
-8.82 (-60.95%)
since 08/14/25

Most Recent Stories

More News
Kaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Securities Class Action Deadline - Contact the Firm Before October 5, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

SPRY : 5.65 (-7.38%)
BAC : 64.49 (+0.62%)
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results

$26.2 million in U.S.  neffy ® net product revenue in Q2 2026; total U.S. epinephrine market share for Type 1 allergies of 5% and 8% share within field-targeted accounts Commercial investment...

SPRY : 5.65 (-7.38%)
Did You Lose Money Investing in ARS Pharmaceuticals Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against SPRY

San Diego, California--(Newsfile Corp. - August 13, 2026) - Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired...

SPRY : 5.65 (-7.38%)
SPRY Deadline Alert: SueWallSt Reminds ARS Pharmaceuticals Inc. (SPRY) Investors of Securities Class Action Deadline on October 5, 2026

A securities class action alleges ARS Pharmaceuticals paired specific, confident statements about a July 1, 2026 CVS Caremark formulary date with only generalized risk language, leaving SPRY investors...

SPRY : 5.65 (-7.38%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY

NEW YORK , Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals, Inc. ("ARS" or the "Company") (NASDAQ: SPRY).  Such investors...

SPRY : 5.65 (-7.38%)
ARS Pharmaceuticals Nears Profitability Timeline While Prescription Growth Masks Cost Questions

Barchart Research What to Expect from SPRY Earnings SPRY Generated August 12, 2026 Current Price $6.05 EPS Estimate $$-0.55 Consensus Rating Strong Buy Average Move 8.49% ARS Pharmaceuticals Nears Profitability...

SPRY : 5.65 (-7.38%)
SPRY UPCOMING DEADLINE: Levi & Korsinsky Alerts ARS Pharmaceuticals Inc. Stockholders of Securities Class Action - Contact the Firm

Allegations focus on ARS Pharmaceuticals' alleged failure to disclose the risk that CVS Caremark's rigid formulary system could push a neffy coverage decision to January 2027, missing the summer...

SPRY : 5.65 (-7.38%)
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

SPRY : 5.65 (-7.38%)
BAC : 64.49 (+0.62%)
SPRY Investors with Losses in Excess of $100K Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

NEW YORK , Aug. 11, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ:...

SPRY : 5.65 (-7.38%)
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK , Aug. 11, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ARS Pharmaceuticals...

SPRY : 5.65 (-7.38%)

Business Summary

ARS Pharmaceuticals Inc. is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions which could lead to anaphylaxis. The company is developing neffy(TM) an intranasal epinephrine product in clinical development for patients and their caregivers...

See More

Key Turning Points

3rd Resistance Point 6.83
2nd Resistance Point 6.34
1st Resistance Point 5.99
Last Price 5.65
1st Support Level 5.15
2nd Support Level 4.66
3rd Support Level 4.31

See More

52-Week High 15.09
Fibonacci 61.8% 11.20
Fibonacci 50% 10.00
Fibonacci 38.2% 8.80
Last Price 5.65
52-Week Low 4.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.